Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
Subscribe to receive alerts once a paper has been published by Oncotarget.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control.
This malicious action will be reported to the FBI.
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025. Learn more here and here.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds. Learn more.
Welcome to Oncotarget, a peer-reviewed, open-access journal that publishes research on all aspects of oncology and related fields. By using Oncotarget and submitting your work for publication, you agree to the following Terms of Service:
Submission of Materials:
All articles, images, and other materials submitted for publication must be original works that have not been published previously or are not under consideration for publication elsewhere. Authors are responsible for obtaining any necessary permissions and licenses for the use of copyrighted materials.
Peer Review Process:
All submitted materials are subject to peer review by experts in the relevant fields. The review process is confidential and anonymous, and the final decision to accept or reject a submission is made at the sole discretion of the editorial board. Authors have the right to appeal editorial decisions.
Open Access:
All articles published in Oncotarget are freely available to the public, and authors retain copyright of their work. Articles are published under the Creative Commons Attribution License (CC BY), which allows others to share and adapt the work, provided the original source is properly cited.
Publication Fees:
Authors are responsible for paying publication fees, which are used to cover the costs of peer review, copyediting, and online hosting.
Ethics:
Authors must adhere to the highest standards of ethical conduct in their research and publication practices. Any misconduct, including plagiarism, falsification, or fabrication of data, will not be tolerated and may result in retraction of the article. Visit Oncotarget's Scientific Integrity to learn more about ethics and publishing standards.
Disclaimer:
The content published in Oncotarget is for informational purposes only and should not be construed as medical advice. The journal and its editors are not responsible for any errors or omissions in the content or for any consequences that may arise from the use of the information provided.
Changes to Terms:
Oncotarget reserves the right to modify these Terms of Service at any time without prior notice. Your continued use of the site and submission of materials after such modifications constitutes your acceptance of the revised Terms of Service.
Thank you for choosing Oncotarget as a platform for your research. We look forward to working with you to advance the field of oncology research.